New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
09:16 EDTLOGI, FTNT, JNJ, TRIP, SRPT, UA, SKX, VDSI, QCOM, DNKN, CAT, ANGI, ONVO, F, GM, FBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Facebook (FB), up 7.6%... Ford (F), up 1.4%... Skechers (SKX), up 8%... Under Armour (UA), up 8.5%... VASCO (VDSI), up 16.6%... Logitech (LOGI), up 14.4%... Fortinet (FTNT), up 9%. ALSO HIGHER: Organovo (ONVO), up 19.6% after entering a 3D bio-printed tissue agreement with a unit of J&J (JNJ). DOWN AFTER EARNINGS: General Motors (GM), down 2.4%... Dunkin' Brands (DNKN), down 7.8%... TripAdvisor (TRIP), down 9.7%... Qualcomm (QCOM), down 5.5%... Caterpillar (CAT), down 2.8%. ALSO LOWER: Angie's List (ANGI), down 18% after Q2 report last night, at least seven downgrades of stock this morning... Sarepta (SRPT), down 6.3% after terminating Chief Scientific Officer Arthur Krieg.
News For FB;GM;F;ONVO;ANGI;CAT;DNKN;QCOM;VDSI;SKX;UA;SRPT;TRIP;JNJ;FTNT;LOGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
October 13, 2014
12:44 EDTSRPTSarepta data supported by DMD study in journal, TheStreet reports
A study published in medical journal PLOS One following the progression of Duchenne muscular dystrophy supports Sarepta's push for accelerated approval of eteplirsen, TheStreet's Adam Feuerstein reports. Reference Link
12:10 EDTGMGM lawyer says 27 people eligible for ignition switch compensation, AP reports
Subscribe for More Information
11:00 EDTFFord adding 850 more jobs at Ford Rouge Center to build new F-150
Subscribe for More Information
10:23 EDTFFord to hire 850 workers for Dearborn Rouge factories, WSJ says
Subscribe for More Information
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
09:23 EDTFTNTHP could buy lower valuation company, says Bernstein
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTJNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
07:02 EDTFFord and Carfax expand partnership
Subscribe for More Information
06:44 EDTGM, FRegulators seeking banks' auto loan data, Reuters reports
Subscribe for More Information
05:15 EDTFBFacebook, Ericsson, XL Axiata innovate to improve Indonesia network performance
Subscribe for More Information
October 12, 2014
19:26 EDTSRPTPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTSRPTCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
17:21 EDTGMTesla ahead of other car makers on semiautonomous driving system, WSJ says
Subscribe for More Information
17:20 EDTQCOMGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
14:18 EDTSRPTNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTSRPTTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use